For the first time in its nine-year history, Neuralink has hired federal lobbyists in Washington, with the scope of work explicitly naming “coverage of such devices” as a focus. That is the regulatory architecture that determines whether US health programs will pay for brain-computer interfaces. Newly filed federal disclosures, reported by Bloomberg Government on 1 June 2026, show that Neuralink engaged the healthcare lobbying firm Jeffrey J. Kimbell & Associates and the BigLaw firm Arnold & Porter Kaye Scholer at the end of April 2026. The Arnold & Porter team on the Neuralink account includes former Wisconsin Democratic Rep. Ron Kind, who served thirteen terms in the House from 1997 to 2023 and sat on the House Ways and Means Committee, the panel that oversees Medicare payment programs.

What the disclosures actually say

The federal Lobbying Disclosure Act filings reported by Bloomberg Government’s Caitlin Oprysko name two registrants working for Neuralink, both with engagement start dates at the end of April 2026. The scope is described as “issues related to the development and commercialization of brain-computer interfaces” and matters related to “coverage of such devices.” The “coverage” framing is the technical phrasing that maps directly to Medicare, Medicaid, and commercial-payer reimbursement determinations. It is not generic regulatory advocacy. It is the explicit infrastructure pre-positioning needed before a medical device can move from clinical-stage to commercial-stage revenue in the US healthcare system.

The disclosures themselves are a regulatory artefact. Under the Lobbying Disclosure Act, registrants must file LD-1 registration forms with the Secretary of the Senate and the Clerk of the House when they begin lobbying activity, with quarterly LD-2 income and activity reports following. The disclosures are publicly indexed at lobbyingdisclosure.house.gov and via the Senate filing system.

Why the two-firm structure matters

Neuralink did not hire one lobbyist. It hired two firms in parallel, each with a distinct positioning.

Jeffrey J. Kimbell & Associates was founded in 1998 and is a healthcare-policy lobbying firm headquartered in Washington, DC. The firm describes its focus as life sciences, including medical devices, pharmaceuticals, biotechnology, provider services, and biodefence. Its current client roster covers more than sixty healthcare entities, and its lobbying revenue in 2025 was approximately $4.475 million across sixty-five clients (per LegiStorm and OpenSecrets registries). The firm’s named issue areas explicitly include Medicare, Medicaid, private sector healthcare, medical liability reform, and the FDA. This is the firm Neuralink hires when the priority is the technical mechanics of coverage determinations, CPT and HCPCS code negotiation, and CMS engagement.

Arnold & Porter Kaye Scholer is a BigLaw firm with a Legislative and Public Policy practice that historically operates at a different layer, focused on broader regulatory strategy, congressional relationships, and Member-of-Congress engagement. Ron Kind sits as Senior Counsel in this practice since January 2024 and is on the Neuralink account. His Ways and Means tenure gives him direct prior committee-level relationships with the Members and staff who currently write Medicare reimbursement policy.

The two-firm structure signals that Neuralink is approaching coverage as a multi-layer fight: technical CMS rulemaking and CPT/HCPCS code architecture handled by the healthcare specialist (Kimbell), and Member-of-Congress level relationship work plus broader legislative strategy handled by Arnold & Porter. This is the same structure that mature medical device incumbents (Medtronic, Boston Scientific, Abbott) maintain in Washington.

Where this fits the BCI reimbursement-architecture thesis

Reimbursement is the gating event for BCI commercial scale-up in the US. The clinical-stage cohort has now generated enough public-domain reimbursement data points to make the architecture visible. CVRx’s Barostim moved from a Category III to a Category I CPT code on 1 January 2026, with the Humana Medicare Advantage policy issued on 14 May 2026 as the first Medicare Advantage coverage statement. Inspire Medical Systems is on the opposite end of the same architecture, having been placed on the CMS WISeR prior-authorisation services list with the company subsequently cutting its 2026 revenue guidance by approximately $125 million at the midpoint. NeuroPace is outside the WISeR list, with the company raising guidance in the same window.

Neuralink does not yet have FDA marketing authorisation for the N1 Implant. The implant remains under FDA Breakthrough Device Designation and is being studied under the PRIME multi-site early feasibility study and its international counterparts (GB-PRIME, CAN-PRIME, UAE). The lobbying engagement at this stage is pre-positioning for the coverage fight that begins the day FDA marketing authorisation arrives. The structural read is that Neuralink is sequencing the policy infrastructure ahead of the clinical authorisation event, not after it.

The Chinese contrast

The Chinese commercial pathway for BCI is moving faster on the reimbursement side than the FDA pathway. Neuracle’s NMPA-approved NEO device received a medical insurance consumable classification code from China’s National Healthcare Security Administration within 48 hours of the March 2026 NMPA approval, in what industry observers labelled “light-speed coding.” The US system has no equivalent mechanism. The pathway is structurally longer, involves multiple CMS rulemaking cycles, and depends on CPT or HCPCS code negotiation through the American Medical Association’s CPT Editorial Panel and the CMS HCPCS workgroup. The Neuralink lobbying hire is a US-specific response to a US-specific gating challenge.

What to watch

The first signal is the first Quarterly LD-2 disclosure filing from Jeffrey J. Kimbell & Associates or Arnold & Porter on the Neuralink account. The April engagement date means the Q2 2026 filing (covering April through June) is the first one that will report dollar income and specific issue advocacy. That filing is due 20 July 2026 and will sharpen the picture of how much Neuralink is spending and on which specific bill numbers, agency rulemakings, or coverage determinations. The second signal is whether Neuralink files for an FDA marketing authorisation in 2026, which would convert the current pre-positioning into an active coverage fight. The third signal is whether other clinical-stage BCI companies (Synchron, Paradromics, Precision Neuroscience) hire their own federal lobbyists in the next two quarters, which would indicate the category-wide reimbursement-architecture fight has become a near-term priority across the cohort rather than a Neuralink-specific move.

Sources

• Musk’s Neuralink Brain Implant Company Hires Federal Lobbyists (Bloomberg Government, 1 June 2026)
• Former Rep. Ron Kind biography (LegiStorm)
• Ron Kind, Senior Counsel, Arnold & Porter
• Jeffrey J. Kimbell & Associates, Healthcare Legislative Solutions
• Jeffrey J Kimbell & Assoc lobbying profile (OpenSecrets)
• Jeffrey J. Kimbell & Associates registrant summary (LegiStorm)